121 related articles for article (PubMed ID: 25824714)
1. [Oncogenetics in the management of ovarian cancer: State-of-the art].
Caron O
Gynecol Obstet Fertil; 2015 May; 43(5):335-7. PubMed ID: 25824714
[No Abstract] [Full Text] [Related]
2. [Olaparib in ovarian cancer with BRCA mutation].
Pujade-Lauraine É; Combe P
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S82-4. PubMed ID: 26118881
[TBL] [Abstract][Full Text] [Related]
3. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
4. [Not Available].
Gladieff L; Lyonnet DS; Lortholary A; Leary A; Genestie C; Ray-Coquard I
Bull Cancer; 2017 May; 104 Suppl 1():S16-S23. PubMed ID: 28625311
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy directly followed by poly(ADP-ribose) polymerase inhibition as an alternative to surgery in patients with BRCA-mutated ovarian cancer: a potential management strategy in the era of coronavirus disease 2019.
Vetter MH; Smrz SA; Copeland LJ; Cohn DE
Am J Obstet Gynecol; 2020 Sep; 223(3):469-470. PubMed ID: 32454030
[No Abstract] [Full Text] [Related]
6. [Role of oncogenetics in the treatment of breast and ovarian cancer].
Langmár Z; Németh M
Orv Hetil; 2011 Jul; 152(30):1214-5. PubMed ID: 21733796
[No Abstract] [Full Text] [Related]
7. Diagnostic histologique et moléculaire des cancers de l'ovaire - recommandations pour la pratique clinique Saint-Paul 2021: Histological and molecular diagnosis of ovarian.
Genestie C; Gladieff L; Frère-Belda ML; Lortholary A; Vaur D; Treilleux I; Lyonnet DS
Bull Cancer; 2021 Dec; 108(9S1):S33-S38. PubMed ID: 34955160
[TBL] [Abstract][Full Text] [Related]
8. BRACAnalysis CDx as a companion diagnostic tool for Lynparza.
Gunderson CC; Moore KN
Expert Rev Mol Diagn; 2015; 15(9):1111-6. PubMed ID: 26292709
[TBL] [Abstract][Full Text] [Related]
9. Olaparib (Lynparza) for advanced ovarian cancer.
Med Lett Drugs Ther; 2016 Feb; 58(1489):e32-3. PubMed ID: 26938702
[No Abstract] [Full Text] [Related]
10. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
[TBL] [Abstract][Full Text] [Related]
11. Using PARP Inhibitors in Frontline Maintenance Therapy for Ovarian Cancer.
Oncology (Williston Park); 2020 Oct; 34(10):442-444. PubMed ID: 33058112
[TBL] [Abstract][Full Text] [Related]
12. [Not Available].
Joly F; Querleu D; Namer M; Pujade-Lauraine E
Bull Cancer; 2017 May; 104 Suppl 1():S1-S5. PubMed ID: 28625310
[TBL] [Abstract][Full Text] [Related]
13. [PARP inhibitors in first-line of ovarian cancers].
Rodrigues M
Bull Cancer; 2020 Jan; 107(1):4-5. PubMed ID: 31928735
[No Abstract] [Full Text] [Related]
14. Targeting triple-negative breast cancer and high-grade ovarian carcinoma: refining BRCAness beyond BRCA1/2 mutations?
Jacot W; Theillet C; Guiu S; Lamy PJ
Future Oncol; 2015; 11(4):557-9. PubMed ID: 25686112
[No Abstract] [Full Text] [Related]
15. Olaparib recommendations for ovarian cancer patients.
Johnson P; Westcott G
Future Oncol; 2016 Jan; 12(2):149-51. PubMed ID: 26616222
[TBL] [Abstract][Full Text] [Related]
16. Comparing poly (ADP-ribose) polymerase inhibitors with standard chemotherapy in BRCA-mutated, recurrent ovarian cancer: lessons learned from a negative trial.
Konstantinopoulos PA; Cannistra SA
J Clin Oncol; 2012 Feb; 30(4):347-50. PubMed ID: 22203759
[No Abstract] [Full Text] [Related]
17. Lack of BRCA testing approval creates snag for cancer trials.
Azvolinsky A
Nat Med; 2012 Sep; 18(9):1310. PubMed ID: 22961142
[No Abstract] [Full Text] [Related]
18. PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers.
Carden CP; Yap TA; Kaye SB
Curr Opin Oncol; 2010 Sep; 22(5):473-80. PubMed ID: 20485165
[TBL] [Abstract][Full Text] [Related]
19. Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions.
Domchek SM
Cancer Discov; 2017 Sep; 7(9):937-939. PubMed ID: 28864639
[TBL] [Abstract][Full Text] [Related]
20. [Oncogénétique dans les cancers de l'ovaire].
Desseignés C; Benusiglio P
Rev Prat; 2022 Jun; 72(6):639-641. PubMed ID: 35899665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]